This executive summary discusses in vitro methodologies used at Lonza for the characterization of bioavailability enhancing formulations, as well as criteria for selecting the right in vitro method based on compound properties and dose. To learn more, please download our executive summary.
Content Type: Whitepaper/Executive Summary
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center

Whitepaper/Executive Summary
Overcome Expression Challenges of New Molecular Formats with Optimized Mammalian Technologies
Lonza's mammalian expression technologies offer commercially viable systems that cover the diversity...
Elution image - blog
Blog post
Harnessing the Power of Peptide Mapping for AAV and Adenovirus based Gene Therapy
As gene therapy developers strive to optimize their products, peptide mapping has emerged as an...
Bend-closer look
Blog post
How CDMOs Can Help Small Biotechs Meet Timeline Goals for Their Product Pipeline
The right integrated CDMO can help a small biotech company move a project into and through the...
Technical/Service brief
Brochure: mRNA/LNP Development and Manufacturing Services
Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable...
Whitepaper/Executive Summary
Current and Emerging Technologies to Optimize mRNA Manufacturing
Messenger RNAs (mRNAs) represent a fast-emerging class of biotherapeutics. They hold considerable...
Sustainability webinar
Webinar (on-demand)
Environmental Sustainability at Lonza Small Molecules - Wastewater Incineration Reduction
Sustainability is at the forefront of the way Lonza runs its business. Thanks to its Vision Zero...
Small-Molecules_Drug-Product-Catalog
Presentation (on-demand)
Amorphous Solid Dispersions for Delivery of Highly Performing Formulations of Oral Oncology...
Oncology compounds are prevalent in pharmaceutical pipelines but many are poorly water soluble in...
Webinar (on-demand)
The Challenges of moving a Bioconjugate Candidate from Clinic to Market
The path to market of a novel drug is complex and uncertain. Under the growing pressure of...
Slough, United Kingdom – Small-scale manufacturing
Blog post
Product Attribute Control and Its’ role in Quality by Design
An overriding mission at Lonza, and for many CDMOs, is to consistently create effective, safe, and...
Webinar (on-demand)
From Early Development into Clinic - De-risking a Bioconjugates journey
The journey of a novel bioconjugate into clinic is complex and uncertain. In this webinar, we...
techs working in lab
Webinar (on-demand)
Process development best practices for CGT commercialization readiness
Our expert introduces some of the bioprocessing best practices required to de-risk the commercial...
Article
Ramp up your AAV production with Lonza’s proprietary HEK293 cell Line and vector technologies
With the AAV market gaining momentum, gene therapy developers are under increasing pressure to...